An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment.
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Anakinra (Primary)
- Indications Adult-onset Still's disease
- Focus Therapeutic Use
- 01 Aug 2012 Results published in The Journal of Rheumatology.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed based on results published in The Journal of Rheumatology.
- 19 Jun 2010 Results presented at the 11th Annual Congress of the European League Against Rheumatism
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History